Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Ophthotech to develop Biogen/PDL's volociximab for AMD

Executive Summary

Biogen Idec and acute care products company PDL BioPharma have licensed Ophthotech (candidates for back-of-the-eye diseases) exclusive worldwide rights to develop and sell their monoclonal antibody volociximab (M200) for ophthalmic indications.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Includes Equity
    • R+D and Marketing-Licensing
    • Reverse Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register